To achieve this outcome regular, typically six-monthly, ultrasound (US) examinations of patients with hepatic cirrhosis is recommended, with or without the tumour marker alpha-fetoprotein (AFP) [2]. This evidence concerns the gene AFP and Cirrhosis.